| DNA-repair defects and olaparib in metastatic prostate cancer J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ... New England Journal of Medicine 373 (18), 1697-1708, 2015 | 2263 | 2015 |
| Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, ... The Lancet Oncology 21 (1), 162-174, 2020 | 558 | 2020 |
| Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition J Goodall, J Mateo, W Yuan, H Mossop, N Porta, S Miranda, ... Cancer discovery 7 (9), 1006-1017, 2017 | 388 | 2017 |
| Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer A Sharp, I Coleman, W Yuan, C Sprenger, D Dolling, DN Rodrigues, ... The Journal of clinical investigation 129 (1), 192-208, 2019 | 334 | 2019 |
| PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate R Ferraldeschi, DN Rodrigues, R Riisnaes, S Miranda, I Figueiredo, ... European urology 67 (4), 795-802, 2015 | 269 | 2015 |
| Genomics of lethal prostate cancer at diagnosis and castration resistance J Mateo, G Seed, C Bertan, P Rescigno, D Dolling, I Figueiredo, ... The Journal of clinical investigation 130 (4), 1743-1751, 2020 | 227 | 2020 |
| Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer DN Rodrigues, P Rescigno, D Liu, W Yuan, S Carreira, MB Lambros, ... The Journal of clinical investigation 128 (10), 4441-4453, 2018 | 204 | 2018 |
| Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration JS Frenel, S Carreira, J Goodall, D Roda, R Perez-Lopez, N Tunariu, ... Clinical Cancer Research 21 (20), 4586-4596, 2015 | 201 | 2015 |
| Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors TA Yap, B O’Carrigan, MS Penney, JS Lim, JS Brown, ... Journal of Clinical Oncology 38 (27), 3195, 2020 | 182 | 2020 |
| Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer D Lorente, D Olmos, J Mateo, D Bianchini, G Seed, M Fleisher, DC Danila, ... European urology 70 (6), 985-992, 2016 | 155 | 2016 |
| Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant … J Welti, DN Rodrigues, A Sharp, S Sun, D Lorente, R Riisnaes, ... European urology 70 (4), 599-608, 2016 | 142 | 2016 |
| SPOP-mutated/CHD1-deleted lethal prostate cancer and abiraterone sensitivity G Boysen, DN Rodrigues, P Rescigno, G Seed, D Dolling, R Riisnaes, ... Clinical cancer research 24 (22), 5585-5593, 2018 | 141 | 2018 |
| Targeting the p300/CBP axis in lethal prostate cancer J Welti, A Sharp, N Brooks, W Yuan, C McNair, SN Chand, A Pal, ... Cancer Discovery 11 (5), 1118-1137, 2021 | 138 | 2021 |
| BRD4 promotes DNA repair and mediates the formation of TMPRSS2-ERG gene rearrangements in prostate cancer X Li, GH Baek, SG Ramanand, A Sharp, Y Gao, W Yuan, J Welti, ... Cell reports 22 (3), 796-808, 2018 | 134 | 2018 |
| Targeting bromodomain and extra-terminal (BET) family proteins in castration-resistant prostate cancer (CRPC) J Welti, A Sharp, W Yuan, D Dolling, D Nava Rodrigues, I Figueiredo, ... Clinical Cancer Research 24 (13), 3149-3162, 2018 | 131 | 2018 |
| Single-cell analyses of prostate cancer liquid biopsies acquired by apheresis MB Lambros, G Seed, S Sumanasuriya, V Gil, M Crespo, M Fontes, ... Clinical Cancer Research 24 (22), 5635-5644, 2018 | 108 | 2018 |
| PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients EA Punnoose, R Ferraldeschi, E Szafer-Glusman, EK Tucker, S Mohan, ... British journal of cancer 113 (8), 1225-1233, 2015 | 98 | 2015 |
| Second-generation HSP90 inhibitor onalespib blocks mRNA splicing of androgen receptor variant 7 in prostate cancer cells R Ferraldeschi, J Welti, MV Powers, W Yuan, T Smyth, G Seed, ... Cancer research 76 (9), 2731-2742, 2016 | 95 | 2016 |
| Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial S Carreira, N Porta, S Arce-Gallego, G Seed, A Llop-Guevara, D Bianchini, ... Cancer discovery 11 (11), 2812-2827, 2021 | 92 | 2021 |
| First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate … D Bianchini, A Omlin, C Pezaro, D Lorente, R Ferraldeschi, D Mukherji, ... British journal of cancer 109 (10), 2579-2586, 2013 | 88 | 2013 |
Johann de BonoInstitute of Cancer ResearchVerified email at icr.ac.uk
